Surotomycin Explained

Surotomycin was an investigational oral antibiotic. This macrolide antibiotic was under investigation by Merck & Co (who acquired Cubist Pharmaceuticals) for the treatment of life-threatening diarrhea, commonly caused by the bacterium Clostridium difficile.[1] After reaching phase III in clinical trials, its production was discontinued in 2017 due to its non-superiority to current therapies.[2] [3]

See also

Notes and References

  1. Web site: Surotomycin Fact Sheet . cubist.com .
  2. P Daley . T Louie . J E Lutz . S Khanna . U Stoutenburgh . M Jin . A Adedoyin . L Chesnel . D Guris . K B Larson . Y Murata . Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial . Journal of Antimicrobial Chemotherapy . 72 . 12 . December 2017 . 3462–3470 . 10.1093/jac/dkx299. 28961905 . free .
  3. Web site: Surotomycin Fails To Show Benefit Over Vancomycin in C. Difficile Treatment in Phase 3 Trial. Jenna Payesko. 24 September 2019. MD magazines.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Surotomycin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.